
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune is well-capitalized with a pro forma cash balance of $535 million and a fully funded development plan for their lead candidate pemvidutide, which has potential for peak annual revenues of over $5.0 billion. The company has successfully aligned with regulatory agencies and has upcoming catalysts for alcohol-related diseases with their Phase 2 trial for AUD data expected in 3Q26 and enrollment completion for their RESTORE trial in ALD, potentially pulling forward the next proof-of-concept milestone. Altimmune's operationalized PERFORMA trial design for pemvidutide in MASH shows potential for tolerability, simple titration, and quality weight loss. Additionally, Altimmune's potential to deliver quality weight loss with lean-mass preservation is a particularly relevant attribute for the projected average age at MASH diagnosis and the onset of clinically meaningful sarcopenia risk. Despite potential competition and clinical risks in the NASH and obesity markets, Altimmune's strong financial position and strategic approach make it a strong candidate for investment with a Buy rating.
Bears say
Altimmune is at risk due to its heavy reliance on the success of its key candidate, pemvidutide, in treating liver diseases which, if hindered by clinical or commercial challenges, would significantly impact the company's future outlook and stock price. Additionally, the company's limited institutional evaluation and need for future capital raises pose financial risks that may result in equity share dilution and negatively affect shareholder value. The company's Q4 2025 financial results also showed expenses exceeding estimates, raising concerns about efficient cash management and future profitability.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares